|
|
|
|
|
|
|
25.06.26 - 13:03
|
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres′ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy. The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.04.26 - 13:03
|
Seres Therapeutics to Present at CARB-X Investor Day (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerating the development of new antibacterial products to address drug-resistant bacteria. The CARB-X Investor Day brings together pharmaceutical and biotech product developers, investors, and partners working to combat antimicrobial resistance (AMR). The World Health Organization declared AMR as a top ten global public health threat, with estimates that yearly deaths may reach 10 million by 2050, putting mortality due to AMR on par with deaths due to cancer. The event will feature presentations on innovative therapeu...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|